Journal Article Summary
The article investigates the similarity between a proposed biosimilar adalimumab, known as MSB11022, and the original product, Humira®. This topic is significant because biosimilars can provide more affordable treatment options for patients with various autoimmune diseases, potentially increasing access to essential therapies. As patents for original biologics expire, the development of biosimilars is crucial for addressing the high costs associated with these medications, which can limit patient access and treatment options.
The study involved a comprehensive analysis comparing three batches of MSB11022 with up to 23 batches of Humira® using advanced analytical methods. The researchers assessed various physicochemical and functional characteristics, including molecular structure, purity, and biological activity. The findings indicated that MSB11022 demonstrated high similarity to Humira® across all tested parameters, suggesting that it is likely to have comparable safety and efficacy profiles.
However, the study does have limitations, including the potential variability in manufacturing processes that could affect the final product. Patients should be aware that while MSB11022 is expected to be similar to Humira®, individual responses to medications can vary. It is essential for patients and caregivers to discuss any concerns or questions about switching to a biosimilar with their healthcare professional to ensure safe and effective treatment options.
Medical Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Magnenat Laurent, Palmese Angelo, Fremaux Christèle, D'Amici Fabio, Terlizzese Mariagrazia, Rossi Mara, Chevalet Laurent. Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®. mAbs 2017. DOI: 10.1080/19420862.2016.1259046. PMID: 27854156. PMCID: PMC5240642.
Featured Pill Pals Product
Adalimumab-ADAZ 40 MG / 0.4 ML Auto Injector x 2 Syringes --- Sandoz Brand --- Bioequivalent to Humira
Adalimumab-ADAZ 40 MG / 0.4 ML Auto Injector x 2 Syringes --- Sandoz Brand --- Bioequivalent to Humira is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription may be required.
